Avsplus Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 08-11-2024
- Paid Up Capital ₹ 3.27 M
as on 08-11-2024
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.00 Cr
as on 08-11-2024
- Satisfied Charges ₹ 4.00 Cr
as on 08-11-2024
- Revenue 28.21%
(FY 2023)
- Profit -26.90%
(FY 2023)
- Ebitda 45.13%
(FY 2023)
- Net Worth 5533.28%
(FY 2023)
- Total Assets 153.13%
(FY 2023)
About Avsplus Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.27 M.
The company currently has active open charges totaling ₹15.00 Cr. The company has closed loans amounting to ₹4.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Yogendra Mungale, Kalpesh Jain, and Deepesh Kolge serve as directors at the Company.
- CIN/LLPIN
U51909MH2021PTC356814
- Company No.
356814
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Avsplus Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogendra Mungale  | Director | 11-Mar-2021 | Current |
| Kalpesh Jain | Director | 11-Mar-2021 | Current |
| Deepesh Kolge | Director | 21-Sep-2022 | Current |
Financial Performance and Corporate Structure Insights of Avsplus Pharma.
Avsplus Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.21% increase. The company also saw a substantial fall in profitability, with a 26.9% decrease in profit. The company's net worth Soared by an impressive increase of 5533.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avsplus Pharma?
In 2023, Avsplus Pharma had a promoter holding of 52.99% and a public holding of 47.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Keshavlal Pharma Solutions Private LimitedActive 4 years 12 days
Yogendra Mungale is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Jan 2023 | ₹15.00 Cr | Open |
Others Creation Date: 30 Nov 2021 | ₹4.00 Cr | Satisfied |
How Many Employees Work at Avsplus Pharma?
Avsplus Pharma has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avsplus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avsplus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
